Cargando…

Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer

Introduction: Castration resistant prostate cancer (CRPC) has been characterized by a reactivation of the androgen receptor (AR) signaling pathway via alterations in androgen metabolism and AR aberrations. High-dose testosterone (HDT) is emerging as an active treatment in metastatic CRPC, however, b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moses, Marcus, Koksal, Ulkuhan, Ledet, Elisa, Manogue, Charlotte, Cotogno, Patrick, Lewis, Brian, Layton, Jodi, Sartor, A. Oliver, Barata, Pedro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967778/ https://www.ncbi.nlm.nih.gov/pubmed/32002120 http://dx.doi.org/10.18632/oncotarget.27408

Ejemplares similares

Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab
por: Hawkins, Charlotte (Manogue), et al.
Publicado: (2022)

Biomarkers for Programmed Death‐1 Inhibition in Prostate Cancer
por: Manogue, Charlotte, et al.
Publicado: (2018)

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
por: Schiff, Joshua P., et al.
Publicado: (2019)

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort
por: Barata, Pedro, et al.
Publicado: (2020)

Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer
por: Ledet, Elisa M., et al.
Publicado: (2021)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020)

Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
por: Barata, Pedro, et al.
Publicado: (2020)

Inherited DNA-repair gene mutations in African American men with prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2020)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2015)

Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer
por: Cao, Subing, et al.
Publicado: (2019)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer
por: Taavitsainen, Sinja, et al.
Publicado: (2019)

A Case Report with Severe Thrombocytopenia Induced by Axitinib
por: Koksal, Ulkuhan I., et al.
Publicado: (2020)

Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
por: Caramella, Irene, et al.
Publicado: (2022)

Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
por: Sartor, A Oliver
Publicado: (2011)

Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer
por: Sartor, Oliver, et al.
Publicado: (2023)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Clinical response in metastatic castration‐resistant prostate cancer (mCRPC) cases treated with supra‐physiological doses of testosterone: Bipolar androgen therapy
por: Hoshi, Senji, et al.
Publicado: (2022)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
por: Gul, Anita, et al.
Publicado: (2019)

Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
por: Lanka, Sree M., et al.
Publicado: (2023)

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
por: Lavaud, Pernelle, et al.
Publicado: (2020)

Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
por: Marshall, Catherine H., et al.
Publicado: (2021)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
por: Perner, Sven, et al.
Publicado: (2015)

THU544 Prostatic Acid Phosphatase Is Negatively Regulated By Androgens And Persists In Castrate-resistant Metastatic Prostate Cancer
por: Rajagopalan, Vinodh, et al.
Publicado: (2023)

Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer
por: Lam, Hung-Ming, et al.
Publicado: (2018)

“Prostate telocytes change their phenotype in response to castration or testosterone replacement”
por: Felisbino, Sérgio Luis, et al.
Publicado: (2019)

Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy
por: von Klot, Christoph A., et al.
Publicado: (2017)

Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents
por: Zhang, Guanyi, et al.
Publicado: (2015)

Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Jang, Ho Seong, et al.
Publicado: (2016)

Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Ryan, Charles J, et al.
Publicado: (2019)

Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
por: Obinata, Daisuke, et al.
Publicado: (2023)

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
por: Wang, Yue, et al.
Publicado: (2017)

Testosterone metabolites inhibit proliferation of castration- and therapy-resistant prostate cancer
por: Bremmer, Felix, et al.
Publicado: (2018)

Discordance between testosterone measurement methods in castrated prostate cancer patients
por: Rouleau, Mélanie, et al.
Publicado: (2019)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_moq943fokv6ju5n82fvv22nmee